Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 25,947 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 25,947 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the sale, the chief executive officer directly owned 377,817 shares in the company, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, May 18th, Richard Nolan Townsend sold 3,342 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.06, for a total transaction of $16,910.52.
• On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00.

Lexeo Therapeutics Stock Down 4.5%

Shares of Lexeo Therapeutics stock traded down $0.21 during trading on Wednesday, reaching $4.45. 852,557 shares of the stock were exchanged, compared to its average volume of 948,339. The stock’s fifty day moving average is $5.16 and its 200 day moving average is $6.67. The firm has a market cap of $349.41 million, a price-to-earnings ratio of -3.07 and a beta of 1.38. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Equities analysts forecast that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after purchasing an additional 1,459 shares during the period. Bank of America Corp DE boosted its position in shares of Lexeo Therapeutics by 6.1% in the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after purchasing an additional 1,626 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Lexeo Therapeutics by 19.5% in the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after buying an additional 2,317 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Lexeo Therapeutics by 25.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock valued at $118,000 after buying an additional 2,427 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. cut their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, June 25th. Chardan Capital restated a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a report on Monday, May 11th. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings downgraded shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.